CYTX - Cytori Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4008
-0.0192 (-4.5714%)
As of 3:43PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.4200
Open0.4200
Bid0.4060 x 100
Ask0.4175 x 1700
Day's Range0.4000 - 0.4678
52 Week Range0.2200 - 2.1300
Volume5,862,632
Avg. Volume1,253,029
Market Cap14.076M
Beta2.86
PE Ratio (TTM)N/A
EPS (TTM)-0.8520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.08
Trade prices are not sourced from all markets
  • SmarterAnalyst14 days ago

    Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today

    Cytori Therapeutics Inc (NASDAQ:CYTX) was Wall Street's bull of the day today with shares that flew 74%. The cause of all the enthusiastic commotion? Japanese drug giant Takeda Pharmaceutical intends to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, at an acquisition price of EUR 1.78 per share, representing a transaction value of approximately EUR 520 million on a fully diluted basis. Investors see the acquisition of Tigenix as a positive "interest" signal for the regenerative medicine space and specifically for Cytori which has a similar adipose based product.

  • Capital Cubelast month

    ETFs with exposure to Cytori Therapeutics, Inc. : December 18, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry?
    Simply Wall St.2 months ago

    Cytori Therapeutics Inc’s (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry?

    Understanding Cytori Therapeutics Inc’s (NASDAQ:CYTX) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...

  • GlobeNewswire2 months ago

    Cytori Closes Rights Offering for Gross Proceeds of $10 Million

    SAN DIEGO, Nov. 28, 2017-- Cytori Therapeutics, Inc. announced today the closing of its rights offering to subscribe for units at a subscription price of $1,000 per unit. Pursuant to the Rights Offering, ...

  • Capital Cube2 months ago

    ETFs with exposure to Cytori Therapeutics, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
    Capital Cube2 months ago

    Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017

    Categories: Yahoo FinanceGet free summary analysis Cytori Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Cytori Therapeutics, Inc. – Baxter International Inc., Retractable Technologies, Inc., Vericel Corporation, Haemonetics Corporation, CryoLife, Inc., Cesca Therapeutics Inc., Caladrius Biosciences, Inc. and Cerus Corporation (BAX-US, RVP-US, VCEL-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CYTX earnings conference call or presentation 9-Nov-17 10:30pm GMT

    Q3 2017 Cytori Therapeutics Inc Earnings Call

  • GlobeNewswire2 months ago

    Cytori Reports Reduction in Fibrosis Parameters in Scar Study

    SAN DIEGO, Nov. 20, 2017-- Cytori Therapeutics, Inc. announced today the publication of preclinical data from a study using Cytori Cell Therapy™ in a model of fibrotic scar formation. This study was performed ...

  • GlobeNewswire2 months ago

    Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS

    Pharmacokinetic Bioequivalence Shown for Cytori’ s ATI-0918 Liposomal Formulation of Doxorubicin Hydrochloride,. Results Presented at the 2017 American Association of Pharmaceutical Scientists Annual Meeting. ...

  • GlobeNewswire2 months ago

    Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21

    SAN DIEGO, Nov. 15, 2017-- Cytori Therapeutics, Inc. provides a reminder to stockholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on Tuesday, November 21, ...

  • GlobeNewswire2 months ago

    Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis

    SAN DIEGO, Nov. 13, 2017-- Cytori Therapeutics, Inc. today announced a new investigator initiated U.S. clinical trial for hip osteonecrosis. Details of the trial can be assessed at https://clinicaltrials.gov/ct2/show/NCT03269409.. ...

  • Associated Press2 months ago

    Cytori reports 3Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 14 cents. The developer of cell therapies posted revenue of $1.8 million in the period. In the final minutes of trading on Thursday, ...

  • GlobeNewswire2 months ago

    Cytori Reports Third Quarter 2017 Business and Financial Results

    SAN DIEGO, Nov. 09, 2017-- Cytori Therapeutics today announced its third quarter 2017 financial results and provided updates on its corporate activity and clinical development. Third quarter 2017 net loss ...

  • GlobeNewswire2 months ago

    STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress

    SAN DIEGO, Nov. 07, 2017-- Cytori Therapeutics, Inc. announced today that its U.S. STAR clinical trial assessing the safety and efficacy of Habeo™ Cell Therapy for hand dysfunction due to systemic scleroderma ...

  • Capital Cube2 months ago

    ETFs with exposure to Cytori Therapeutics, Inc. : November 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • GlobeNewswire3 months ago

    Cytori to Webcast Third Quarter Financial Results on November 9

    SAN DIEGO, Nov. 02, 2017-- Cytori Therapeutics, Inc. will provide a live webcast of its third quarter financial results and business update on Thursday, November 9, 2017 at 5:30 PM Eastern Time.. The dial-in ...

  • Should You Buy Cytori Therapeutics Inc (CYTX) Now?
    Simply Wall St.3 months ago

    Should You Buy Cytori Therapeutics Inc (CYTX) Now?

    Cytori Therapeutics Inc (NASDAQ:CYTX), a biotechnology company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in the over the last fewRead More...

  • Capital Cube3 months ago

    ETFs with exposure to Cytori Therapeutics, Inc. : October 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Cytori Therapeutics and Repros Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 9, 2017 / U.S. markets pulled back Friday as data showed U.S. nonfarm jobs declined for the first time in seven years. The Dow Jones Industrial Average declined 0.01 ...

  • Capital Cube4 months ago

    ETFs with exposure to Cytori Therapeutics, Inc. : September 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube4 months ago

    ETFs with exposure to Cytori Therapeutics, Inc. : September 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Cytori Therapeutics, Inc. : August 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cytori Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CYTX-US. Comparing the performance and risk of Cytori Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • TheStreet.com5 months ago

    Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

    A number of biotech-related stocks were down pre-market after announcing plans for public offerings.